Trials / Completed
CompletedNCT03100864
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to understand the mechanism of action of BI655130 in patients with UC Secondary objectives are to explore clinical effect, safety and tolerability (including immunogenicity) of BI 655130 treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spesolimab | 12 weeks treatment |
Timeline
- Start date
- 2017-05-22
- Primary completion
- 2019-08-05
- Completion
- 2019-10-24
- First posted
- 2017-04-04
- Last updated
- 2025-10-16
- Results posted
- 2020-11-16
Locations
4 sites across 3 countries: Belgium, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT03100864. Inclusion in this directory is not an endorsement.